The pharmaceutical landscape is entering a phase of unprecedented focus on immune-mediated diseases, with research teams racing to develop treatments for conditions ranging from autoimmune disorders to chronic inflammatory diseases. The key to this progress is not just advanced molecular tools—it is also the strategic use of robust preclinical disease models that faithfully recapitulate...